Table 2 Details of trials included in IAC treatment based on ICRB grading
Authors | Mean follow -up (months) | Globe salvage in different group eyes (%) | Overall Success Rate (%) | Second Tumor Rate (%) | Metastasis Rate (%) | Recurrence Rate (%) | Secondary treatment success rate (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
A (n = 0) | B (n = 12) | C (n = 17) | D (n = 148) | E (n = 49) | |||||||
Thampi2013 | 14.5 | 85.7(6/7) | 38.5(5/13) | 55.0(11/20) | NA | 0.0(0/20) | NA | NA | |||
Gobin2011 | 24.0 | NA | NA | NA | NA | NA | 81.7(35/43) | NA | NA | NA | 58.4(30/52) |
Abramson2016 | 34.0 | NA | NA | NA | 85.1(40/47) | NA | 78.6(88/112) | 0.0(0/112) | 2.7(3/112) | NA | 72.4(42/58) |
Shields2014 | 19.0 | NA | 100.0(1/1) | 100.0(4/4) | 94.1(16/17) | 35.7(5/14) | 72.2(26/36) | NA | 0.0(0/70) | NA | 61.8(21/34) |
Chen2017 | 13.6 | NA | 100.0(11/11) | 100.0(11/11) | 78.6(44/56) | 62.1(18/29) | 78.5(84/107) | NA | NA | 11.2(12/107) | 79.0(49/62) |
Tuncer2016 | 29.0 | NA | NA | NA | 66.6(16/24) | NA | NA | NA | NA | 29.2(7/24) | NA |
Shields2011 | 18.0 | NA | NA | 100.0(2/2) | 100.0(4/4) | 33.3(2/6) | 66.7(8/12) | 0.0(0/16) | 0.0(0/16) | 18.8(3/16) | 50.0(2/4) |
Fabian2017 | 38.7 | NA | NA | NA | NA | NA | NA | NA | 0.0(0/77) | 1.3(1/77) | NA |
Munier2017 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 24.0(6/25) | NA |